Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Holding(s) in Company

8 Apr 2013 17:41

RNS Number : 8560B
Healthcare Investment Opportunities
08 April 2013
Β 

ο»Ώ

Financial Services Authority

Β 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

Β 

Healthcare Investment Opportunities Plc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

Β 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

Β 

Β 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

Β 

An event changing the breakdown of voting rights

Β 

Other (please specify):

Β 

3. Full name of person(s) subject to thenotification obligation:

Legal & General Group Plc (Group)

Β 

Legal & General Investment Management Limited (LGIM)

Β 

Legal & General Group Plc (L&G)

4. Full name of shareholder(s) Β (if different from 3.):

Legal & General Assurance Society Limited (LGAS & LGPL)

Β 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

Β 

05 April 2013

6. Date on which issuer notified:

08 April 2013

7. Threshold(s) that is/are crossed orreached:

Β 

Group (Above 5%)

Β 

LGIM (Above 5%)

Β 

L&G (Above 3%)

Β 

8. Notified details:

Β 

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Β 

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

Ordinary 1p

Β Below 3%

L&G

6,000,000

6,000,000

14.81%

Β Below 5%

LGIM

(As on First notification under DTR Source Book)

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Β 

Type of financialinstrument

Β 

Expirationdate

Β 

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

Β 

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Β 

Type of financialinstrument

Β 

Β 

Exercise price

Β 

Expiration date

Β 

Exercise/Conversion period

Β 

Number of voting rights instrument refers to

Β 

Β 

% of voting rights

Β 

Β 

Β 

Nominal

Delta

Β 

Β 

Β 

Β 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

Β 

Β 6,000,000

(L&G)

Β 

14.81%

Β 6,000,000

(LGIM)

14.81%

Β 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

Β 

Legal & General Group Plc (Direct and Indirect) (Group) ( 6,000,000 -14.81%= Total Position)

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) ( 6,000,000 - 14.81%= Total Position)

Legal & General Investment Management Limited (Indirect) (LGIM) ( 6,000,000 - 14.81%= Total Position)

Legal & General Group Plc (Direct) (L&G) ( 6,000,000 - 14.81%=LGAS, LGPL & PMC)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Insurance Holdings Limited (Direct) (LGIH) ( 6,000,000 - 14.81%= LGAS & LGPL)

Legal & General Assurance (Pensions Management) Limited (PMC)

Legal & General Assurance Society Limited (LGAS & LGPL) ( 6,000,000 - 14.81%= LGAS & LGPL)

Legal & General Pensions Limited (Direct) (LGPL)

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will ceaseto hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

Β 

Β 

Β 

13. Additional information:

Notification using the total voting rights figure of 40,500,000

14. Contact name:

Angela Hayter (LGIM)

15. Contact telephone number:

020 3124 3851

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
HOLEAKLPEDNDEFF
Date   Source Headline
30th Aug 201711:21 amRNSResult of AGM
30th Aug 20177:00 amRNSAGM Statement
26th Jul 20177:00 amRNSPosting of Annual Report & notice of AGM
25th Jul 201711:36 amRNSDirector/PDMR Shareholding
25th Jul 20177:15 amRNSHardman Research: Transition to sustainable growth
13th Jul 201711:39 amRNSDirector/PDMR Shareholding
11th Jul 20177:00 amRNSFinal Results
7th Jul 20177:00 amRNSFirst patient enrolment in ChondroMimetic® study
19th Jun 20177:00 amRNSNotice of Results
13th Jun 20177:00 amRNSProvisional patent submitted
11th May 20177:15 amRNSHardman Research: Trading:earnings above forecasts
25th Apr 20177:00 amRNSTrading Update
24th Apr 20177:00 amRNSConsolidation of US R&D activities & Board change
10th Apr 20177:00 amRNSCollagen Based Spray Adhesive Poster Presented
3rd Apr 201711:22 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSAgreement signed with Smart Matrix Limited
31st Mar 20174:52 pmRNSHolding(s) in Company
29th Mar 20177:00 amRNSPericardium Divisional Patent in Australia
27th Mar 201712:39 pmRNSDirector/PDMR Shareholding
24th Mar 20179:26 amRNSDirector/PDMR Shareholding
23rd Mar 20177:00 amRNSAttending UK Investor Show
20th Mar 20178:56 amRNSIntroduces new online sales initiative in the US
15th Mar 20179:58 amRNSHolding(s) in Company
14th Mar 20173:28 pmRNSHolding(s) in Company
13th Mar 201711:52 amRNSHardman Research: Engineering cartilage repairs
13th Mar 20179:57 amRNSHolding(s) in Company
13th Mar 20177:05 amRNSHardman Research: Engineering cartilage repairs
9th Mar 20177:00 amRNSHolding(s) in Company
9th Mar 20177:00 amRNSHolding(s) in Company
9th Mar 20177:00 amRNSAttending AAOS and ORS meetings in San Diego
8th Mar 20177:00 amRNSDirector/PDMR Shareholding
7th Mar 20174:08 pmRNSHolding(s) in Company
7th Mar 20171:01 pmRNSDirector/PDMR Shareholding
7th Mar 201711:19 amRNSHolding(s) in Company
7th Mar 20179:56 amRNSHolding(s) in Company
6th Mar 20172:24 pmRNSResult of General Meeting
20th Feb 20177:00 amRNSInvestor presentation
15th Feb 201711:29 amRNSGrant of Options
14th Feb 201711:24 amRNSHardman Research: Funding accelerated growth
14th Feb 20177:00 amRNSPlacing Open Offer and Debt Financing
7th Feb 20177:00 amRNSAttends MD&M West Conference in Anaheim
19th Jan 20177:00 amRNSNew Scientific Advisory Board appointments
13th Jan 20177:00 amRNSThird Medical Research Scotland Ph.D. Studentship
21st Dec 201612:06 pmRNSHardman Research: Foundations for strategic growth
19th Dec 20167:00 amRNSHalf-year Report
14th Dec 20167:00 amRNSPoster Presentation at TERMIS-AM
2nd Dec 20167:00 amRNSNotice of Results
13th Oct 20167:00 amRNSTrading Statement
3rd Oct 20167:00 amRNSChange of Adviser
15th Sep 20167:00 amRNSParticipation in major Horizon 2020 project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.